Respiratory failure & ventilation

Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study

Crit CarePublished Retrospective cohort study

Authors' conclusion

This retrospective propensity-score matched study showed that spontaneously breathing COVID-19 patients on HFNC/ NIV support had a decreased in-hospital mortality risk with iNO use in a time-to-event analysis. Both intubated and spontaneously breathing patients had improvement in oxygenation parameters with iNO therapy but were associated with longer in-hospital stays, ICU stays, ventilation duration, and higher incidence of creatinine rise.

Study context

Population
COVID-19 patients in the SCCM VIRUS COVID-19 registry at Mayo Clinic sites, March 2020–June 2022, requiring high-flow nasal cannula (HFNC), non-invasive ventilation (NIV) or invasive mechanical ventilation1,879 spontaneously breathing, 888 intubated
Participants
2,767 patients
Exposure
Inhaled nitric oxide (iNO) vs no iNO, in spontaneously breathing and intubated patients
  • Spontaneously breathing, iNOn = 153
  • Intubated, iNOn = 193
Outcome
In-hospital mortality (time-to-event, Cox model)
Methodological detailsmulticentre, propensity-score matched, inverse propensity of treatment weighting
  • Multicentre
  • Propensity-score matched
  • Inverse propensity of treatment weighting

Main finding

As reported in the abstract

Hazard ratio (95% CI)
Spontaneously breathing, iNO vs Spontaneously breathing, no iNOPSM
0.49(0.32–0.75)
Spontaneously breathing, iNO vs Spontaneously breathing, no iNOIPTW
0.40(0.26–0.62)
Intubated, iNO vs Intubated, no iNOPSM
0.90(0.66–1.24)
Intubated, iNO vs Intubated, no iNOIPTW
0.98(0.73–1.31)

Observational data: associations, not effects.

Further findings

OutcomeOR (CI)
Intubation risk (spontaneously breathing)Spontaneously breathing, iNO vs Spontaneously breathing, no iNO · PSM1.08 (0.71–1.65)
Intubation risk (spontaneously breathing)Spontaneously breathing, iNO vs Spontaneously breathing, no iNO · IPTW1.10 (0.90–1.33)

Intubation risk (spontaneously breathing)

No significant difference in intubation risk with iNO

FiO2 requirement, P/F ratio, respiratory rate · within 48 h of iNO use

Consistent improvement with iNO in both spontaneously breathing and intubated groups

Hospital stay, ICU stay, ventilation duration

iNO associated with longer hospital and ICU stays and ventilation duration

Safety

Creatinine rise

Higher incidence with iNO

Original publication

Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study. Crit Care. Published 25 October 2024. doi:10.1186/s13054-024-05093-w

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.